减少和预防青少年自杀的移动技术-猫眼课题宝

减少和预防青少年自杀的移动技术

批准号：

10154817

负责人：

Seth Feuerstein

金额：

$39.9万

依托单位：

OUI THERAPEUTICS, INC

依托单位国家：

美国

项目类别：

财政年份：

2021

资助国家：

美国

项目状态：

已结题

起止时间：

2021-02-15 至 2022-08-14

来源：

https://reporter.nih.gov/project-details/10154817

关键词：

Adolescent Adult Aftercare Age Android Anxiety Apple Caring Cause of Death Centers for Disease Control and Prevention (U.S.)Child Clinical Clinical Trials Clinical Trials Cooperative Group Cognitive Therapy Data Development Devices Feasibility Studies Feedback Feeling suicidal Future General Population Goals Heart Diseases Hospitalization Hospitals Individual Inpatients Intervention Life Measures Outcome Participant Patients Phase Population Production Publishing Questionnaires Randomized Controlled Trials Research Risk Sampling Site Sleeplessness Small Business Innovation Research Grant Soldier Suicide Suicide attempt Suicide prevention Teenagers Testing Therapeutic Therapy Clinical Trials Time United States Visit Work Youth acceptability and feasibility adolescent suicide age group aged base cohort commercialization congenital anomaly design digital effective intervention effective therapy efficacy testing experience feasibility testing high risk mobile application mobile computing mortality open label prevent programs reducing suicide smartphone Application substance use suicidal suicidal behavior suicidal morbidity suicidal risk suicide rate treatment as usual trend usability young adult

项目摘要

项目成果

Seth Feuerstein的其他基金

相似基金

相关文献

中文摘要

翻译

摘要自杀是美国青少年死亡的两大原因，增加尽管如此，关于旨在减少自杀的移动的技术的研究仍然很少年轻人的尝试。在第一阶段SBIR申请中，Oui Therapeutics，LLC提出了一个项目：1）创建为青少年（13 - 17岁）提供Aviva-Y测试版; 2）测试测试版的可行性和可接受性 Aviva-Y的单组、开放标签试验。成功实现第一阶段项目的目标将产生一个版本的Aviva-Y，准备在临床试验中测试稳定患者的疗效。长远来说，这项计划会透过发展移动的技术，干预措施。

英文摘要

ABSTRACT Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide attempts among youth. In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta version of Aviva-Y in a single-group, open-label trial. Successful execution of the goals of this Phase I project will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial. In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the development of mobile technology designed to advance the delivery and dissemination of effective interventions.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文